Pharmaceutical - Financial, Eli Lilly

Filter

Current filters:

FinancialEli Lilly

Popular Filters

Eli Lilly 2nd-qtr sales takes hit from generics; net income falls 39%

24-07-2014

US pharma major Eli Lilly reported second quarter 2014 revenues fell 17% to $4.935 billion, reflecting…

Eli LillyFinancialPharmaceutical

Eli Lilly 1st-qtr 2014 net income plunges, sales down, hit by generic competition

24-04-2014

US pharma major Eli Lilly posted first-quarter 2014 financial results, with revenue declined 16 % to…

Eli LillyFinancialPharmaceutical

Eli Lilly sales beat forecasts, despite 2% decline

Eli Lilly sales beat forecasts, despite 2% decline

30-01-2014

US pharma major Eli Lilly has reported financial results, showing that global sales in the fourth quarter…

Eli LillyFinancialPharmaceutical

Eli Lilly forecasts 2014 earnings decline, in line with expectations

Eli Lilly forecasts 2014 earnings decline, in line with expectations

07-01-2014

US drug major Eli Lilly, ahead of reporting fourth-quarter/full year 2013 results later this month, has…

Eli LillyFinancialPharmaceutical

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

10-12-2013

Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Eli Lilly to invest further $700 million to boost insulin production

Eli Lilly to invest further $700 million to boost insulin production

14-11-2013

US pharma major Eli Lilly plans to invest more than $700 million to enhance its global insulin manufacturing…

DiabetesEli LillyFinancialPharmaceuticalProductionResearch

Eli Lilly exceeds expectations with third quarter results

Eli Lilly exceeds expectations with third quarter results

24-10-2013

US pharma major Eli Lilly has announced financial results for the third quarter of 2013. Despite the…

AlimtaAmyvidAxironCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraTrajentaZyprexa

Lilly reveals strong pipeline as it seeks to recover from reaching patent cliff

Lilly reveals strong pipeline as it seeks to recover from reaching patent cliff

04-10-2013

Eli Lilly hopes to launch new medicines to treat unmet patient needs in an aim to return the company…

Eli LillyFinancialNorth AmericaPharmaceutical

Geropharm to invest $45 million in Russian insulin production

Geropharm to invest $45 million in Russian insulin production

25-09-2013

Geropharm, one of Russia’s leading pharmaceutical and biotech companies, is establishing a plant for…

DiabetesEli LillyEuropeFinancialGeropharmNovo NordiskPharmaceuticalProductionSanofi

TVM Life Science Ventures invests in Ixchelsis

09-08-2013

Canada-based TVM Life Science Ventures VII has announced the fund's second investment, with Ixchelsis…

Eli LillyFinancialIX-01IxchelsisMen's HealthPfizerPharmaceuticalResearch

Eli Lilly records higher than expected earnings in 2nd-qtr results

24-07-2013

US drug major Eli Lilly's (NYSE: LLY) recorded higher than expected earnings as growth in key products…

AlimtaCialisCymbaltaEffientEli LillyEvistaFinancialForteoHumalogNorth AmericaPharmaceuticalStratteraZyprexa

Eli Lilly posts sales and EPS declines for 4th-qtr and full year 2012, but beats forecasts

30-01-2013

US pharmaceutical major Eli Lilly (NYSE: LLY) revealed yesterday that fourth quarter 2012 revenue declined…

Eli LillyFinancialPharmaceutical

Eli Lilly financial guidance beats expectations

07-01-2013

Shares of US drug major Eli Lilly (NYSE: LLY) ended Friday up nearly 4% at $51.56, after the company…

Eli LillyFinancialPharmaceutical

Eli Lilly 3rd-qtr 2012 sales fall on Zyprexa generic competition

25-10-2012

US pharma major Eli Lilly (NYSE: LLY) yesterday reported third-quarter 2012 financial results, showing…

Eli LillyFinancialPharmaceutical

Lilly halts development of schizophrenia candidate pomaglumetad methionil

30-08-2012

US drug major Eli Lilly (NYSE: LLY) saw its shares dip less than 1% to $44.51 in morning trading yesterday,…

Eli LillyFinancialNeurologicalPharmaceuticalpomaglumetad methionilResearch

AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance

10-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb's…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbDiabetesEli LillyFinancialLicensingPharmaceutical

Eli Lilly 2nd-qtr sales and earnings tumble on Zyprexa patent expiry, but still beat forecasts

26-07-2012

US drug major Eli Lilly (NYSE: LLY) reported that second-quarter 2012 worldwide revenue declined 10%…

Eli LillyFinancialPharmaceutical

Eli Lilly posts 1st-qtr sales and earnings down, but still beats forecasts

26-04-2012

US drug major Eli Lilly (NYSE: LLY) reported that first-quarter 2012 worldwide revenue declined 4% to…

Eli LillyFinancialPharmaceutical

Eli Lilly results hammered by Zyprexa patent loss

01-02-2012

US drug major Eli Lilly (NYSE: LLY) said that fourth-quarter 2011 global sales dropped 2% to $6.05 billion.…

Eli LillyFinancialPharmaceutical

Eli Lilly falls as 2012 forecasts disappoint

06-01-2012

US drug major Eli Lilly (NYSE: LLY) saw its shares fall 2.6% to 39.66 in mid-morning trading after the…

Eli LillyFinancialPharmaceuticalZyprexa

Eli Lilly 3rd-qtr 2011 sales grow 9% but costs hit profits

21-10-2011

US drug major Eli Lilly (NYSE: LLY) posted financial results for the third quarter of 2011 showing that,…

Eli LillyFinancialPharmaceutical

Back to top